Abstract
Background
CD151, c-Met, and integrin alpha3/alpha6 are all involved in the hepatocyte growth factor (HGF)/c-Met signal pathway, which plays an important role in the malignant progression of tumors.
Aims
The purpose of this study was to explore the expression and prognostic significance of these proteins in pancreatic ductal adenocarcinoma (PDAC).
Methods
We used immunohistochemical methods to investigate the expression patterns of CD151, c-Met, and integrin alpha3/alpha6proteins in 71 patients with PDAC and in ten samples of normal pancreatic tissue. We also assessed correlations between these proteins and clinicopathological parameters and survival of PDAC patients using various statistical methods.
Results
CD151, c-Met, and integrin alpha3/alpha6 were all overexpressed in PDAC. CD151 and c-Met overexpressions were significantly associated with TNM stage (p = 0.001 and p = 0.038, respectively) and lymph node invasion (p = 0.000, p = 0.012, respectively). A significant positive linear correlation was found between CD151 and c-Met (r = 0.583; p = 0.000), integrin alpha3 (r = 0.457; p = 0.000), and integrin alpha6 (r = 0.671; p = 0.000). Overexpression of CD151, c-Met, integrin alpha3, or integrin alpha6 was related to poor survival of PDAC patients (p = 0.000, p = 0.000, p = 0.005, and p = 0.003, respectively), and CD151 and c-Met were independent factors in prognosis of PDAC.
Conclusions
CD151, c-Met, and integrin alpha3/alpha6 were all overexpressed in PDAC. CD151 and c-Met might be new molecular markers to predict the prognosis of PDAC patients.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249.
Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606–1625.
Carpelan-Holmström M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385–387.
Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40–55.
Zheng ZZ, Liu ZX. CD151 gene delivery increases eNOS activity and induces ECV304 migration, proliferation and tube formation. Acta Pharmacol Sin. 2007;28:66–72.
Winterwood NE, Varzavand A, Meland MN, et al. A critical role for tetraspanin CD151 in α3β1 and α6β4 integrin dependent tumor cell functions on laminin-5. Mol Biol Cell. 2006;17:2707–2721.
Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397–422.
Hong IK, Jin YJ, Byun HJ, et al. Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways. J Biol Chem. 2006;281:24279–24292.
Testa JE, Brooks PC, Lin JM, et al. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 1999;59:3812–3820.
Hashida H, Takabayashi A, Tokuhara T, et al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer. 2003;89:158–167.
Ang J, Lijovic M, Ashman LK, et al. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev. 2004;13:1717–1721.
Tokuhara T, Hasegawa H, Hattori N, et al. Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res. 2001;7:4109–4114.
Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009;49:491–503.
Gesierich S, Paret C, Hildebrand D, et al. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res. 2005;11:2840–2852.
Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6:801–811.
Yauch RL, Kazarov AR, Desai B, et al. Direct extracellular contact between integrin a(3)β(1) and TM4SF protein CD151. J Biol Chem. 2000;275:9230–9238.
Sterk LM, Geuijen CA, Oomen LC, et al. The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin a6h4 and may regulate the spatial organization of hemidesmosomes. J Cell Biol. 2000;149:969–982.
Löhr M, Trautmann B, Göttler M, et al. Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas. 1996;12:248–259.
Sawai H, Funahashi H, Matsuo Y, et al. Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci. 2003;48:1241–1250.
Sawai H, Okada Y, Funahashi H, et al. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol. 2006;7:8.
Nishimori H, Yasoshima T, Denno R, et al. A newperitoneal dissemination model established from the human pancreatic cancer cell line. Pancreas. 2001;22:348–356.
Linder S, Castanos-Velez E, von Rosen A, et al. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology. 2001;48:1321–1327.
Weinel RJ, Rosendahl A, Neumann K, et al. Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. Int J Cancer. 1992;52:827–833.
Klosek SK, Nakashiro K, Hara S, et al. CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun. 2005;336:408–416.
Klosek SK, Nakashiro K, Hara S, et al. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. Biochem Biophys Res Commun. 2009;379:1097–1100.
Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–925.
Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005;113:678–682.
Amemiya H, Kono K, Itakura J, et al. c-Met expression in gastric cancer with liver metastasis. Oncology. 2002;63:286–296.
Ebert M, Yokoyama M, Friess H, et al. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res. 1994;54:5775–5778.
Sobin LH, Gospodarowicz MK, Wittekind C. UICC-TNM Classification of Malignant Tumours. New York, NY: Wiley-Liss; 2009.
Lüttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal adenocarcinomas is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000;191:154–161.
Stipp CS, Kolesnikova TV, Hemler ME. Functional domains in tetraspanin proteins. Trends Biochem Sci. 2003;28:106–112.
Hasegawa H, Nomura T, Kishimoto K, et al. SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with α5β1 integrin and regulates adhesion of human T cell leukemia virus type1-infected T cells to fibronectin. J Immunol. 1998;161:3087–3095.
Yáñez-Mó M, Alfranca A, Cabañas C, et al. Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions. J Cell Biol. 1998;141:791–804.
Takeda Y, Kazarov AR, Butterfield CE, et al. Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood. 2007;109:1524–1532.
Zijlstra A, Lewis J, Degryse B, et al. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell. 2008;13:221–234.
Hirano C, Nagata M, Noman AA, et al. Tetraspanin gene expression levels as potential biomarkers for malignancy of gingival squamous cell carcinoma. Int J Cancer. 2009;124:2911–2916.
Yang XH, Richardson AL, Torres-Arzayus MI, et al. CD151 accelerates breast cancer by regulating alpha6 integrin function, signaling, and molecular organization. Cancer Res. 2008;68:3204–3213.
Yauch RL, Berditchevski F, Harler MB, et al. Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell. 1998;9:2751–2765.
Nishiuchi R, Sanzen N, Nada S, et al. Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151. Proc Natl Acad Sci USA. 2005;102:1939–1944.
Lammerding J, Kazarov AR, Huang H, et al. Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci USA. 2003;100:7616–7621.
Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369:1742–1757.
Chattopadhyay N, Wang Z, Ashman LK, et al. alpha3beta1 integrin-CD151, a component of the cadherin–catenin complex, regulates PTPmu expression and cell–cell adhesion. J Cell Biol. 2003;163:1351–1362.
Shigeta M, Sanzen N, Ozawa M, et al. CD151 regulates epithelial cell–cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J Cell Biol. 2003;163:165–176.
Schmelz M, Cress AE, Scott KM, et al. Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia. 2002;4:243–254.
Jiang WG, Martin TA, Parr C, et al. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53:35–69.
Berditchevski F, Odintsova E, Sawada S, et al. Expression of the palmitoylation-deficient CD151 weakens the association of alpha3beta1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling. J Biol Chem. 2002;277:36991–37000.
Acknowledgments
This work was supported by a grant (No. 09QA1404600) from the Science and Technology Commission of Shanghai Municipality awarded to the Department of Shanghai Key Laboratory of Pancreatic Diseases, Shanghai Jiao Tong University.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guang-Hui Zhu and Chen Huang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zhu, GH., Huang, C., Qiu, ZJ. et al. Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma. Dig Dis Sci 56, 1090–1098 (2011). https://doi.org/10.1007/s10620-010-1416-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-010-1416-x